NCT04362644RecruitingPhase 1
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 2 Mar 2020
- Start date
- 8 Dec 2020
- Primary completion date
- Jun 2027
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT04362644
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From 8 Dec 2020 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects with prior radiation therapy to the thorax.
Other illness
- Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
- Diagnoses of current infection by clinical or microbial assessments.
- Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
- Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.
- Subjects with known liver disease.
- Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.
Other
- Acute exacerbation of IPF within \<30 days
- Treatment for \>14 days within the preceding month with \>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.
- Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
- Active cigarette smoking or vaping
Who the study is looking for
- Age between 40-85 years old.
- A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
- Ability and willingness to give informed consent and adhere to study requirements.
- Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \>0.70.
- High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.
Age in the registry: 40 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.